imprOving Adherence to Pulmonary artErial hyperteNsion Treatment With teLemedicIne and patieNt guidaNce
Recruiting · NCT06850792 · Interventional (participants receive a specific treatment) · Lead sponsor: University of Sao Paulo General Hospital
View the official record on ClinicalTrials.gov →Interventions studied
Telemedicine-Based Adherence Support
What this trial is about
Pulmonary arterial hypertension (PAH) is a progressive condition with high morbidity, frequent hospitalizations, and risk of right heart failure. Despite advances in treatment, poor adherence remains a major challenge. This randomized controlled study assesses whether remote monitoring can improve treatment adherence, clinical outcomes, and side effect management in PAH patients on oral therapy.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Adults aged ≥18 years diagnosed with pulmonary arterial hypertension (PAH) (Group 1 of the WHO classification).
- Stable oral PAH therapy (including endothelin receptor antagonists, phosphodiesterase-5 inhibitors, or prostacyclin pathway agents) for at least four weeks prior to enrollment.
- Ability to participate in remote teleconsultations (access to a phone or internet).
- Signed informed consent agreeing to study participation.
Exclusion criteria
- Severe cognitive impairment or psychiatric disorders that could affect adherence or study participation.
- Inability to communicate via phone or telemedicine due to technical or personal constraints.
- Concurrent participation in another interventional clinical trial that could interfere with outcomes.
- Life expectancy \<6 months due to any condition unrelated to PAH.
- Pregnancy or breastfeeding.
Where it is running
1 location listed.
- InCor - Universidade de São Paulo - São Paulo, São Paulo, Brazil